Entellus Medical is focused on providing unique solutions to the unmet needs of the ENT (ear, nose and throat) physician, their patients, and payers through the development of innovative device technology and treatment solutions. The Company provides a simple, direct and effective treatment for Chronic Rhinosinusitis (CRS) that is less invasive, reduces pain and bleeding, shortens recovery time, and eliminates the need for general anesthesia. Entellus recently introduced FinESS Sinus Treatment, a simple and direct approach to effectively treat patients with CRS. FinESS can be performed under local anesthesia, with or without light sedation, and remodels the maxillary ostium and the ethmoid infundibulum using a microendoscope and a small balloon catheter. Unlike sinus surgery techniques, FinESS does not require the removal of delicate bone or sinus tissue, resulting in shorter treatment time with very little pain or bleeding. Recovery time is usually one to two days with many patients resuming normal activity within a day.

Show more
Type
Public
HQ
Plymouth, US
Founded
2006
Size (employees)
280 (est)
Entellus Medical was founded in 2006 and is headquartered in Plymouth, US
Report incorrect company information

Key People/Management at Entellus Medical

Brian Farley

Brian Farley

President, CEO & Board Chairman
Margaret Boiano

Margaret Boiano

VP, Healthcare Policy & Reimbursement
Stephen Paidosh

Stephen Paidosh

VP, Operations
Show more

Entellus Medical Office Locations

Entellus Medical has an office in Plymouth
Plymouth, US (HQ)
3600 Holly Lane North
Show all (1)
Report incorrect company information

Entellus Medical Financials and Metrics

Entellus Medical Revenue

Embed Graph
Entellus Medical's revenue was reported to be $75.18 m in FY, 2016 which is a 22.1% increase from the previous period.
USD

Revenue (Q2, 2017)

22.1 m

Gross profit (Q2, 2017)

16.3 m

Gross profit margin (Q2, 2017), %

73.6%

Net income (Q2, 2017)

(8 m)

EBIT (Q2, 2017)

(7.6 m)

Market capitalization (26-Feb-2018)

598.9 m

Cash (30-Jun-2017)

62.9 m

EV

545.2 m
Entellus Medical's current market capitalization is $598.9 m.
Annual
USDFY, 2015FY, 2016

Revenue

61.6 m75.2 m

Revenue growth, %

22%

Cost of goods sold

14.1 m18.7 m

Gross profit

47.5 m56.5 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

15.2 m14.8 m16.9 m18.7 m17.9 m19.1 m22.1 m

Cost of goods sold

3.3 m3.4 m4 m4.5 m4.6 m4.9 m5.8 m

Gross profit

11.8 m11.4 m12.9 m14.3 m13.2 m14.2 m16.3 m

Gross profit Margin, %

78%77%76%76%74%74%74%
Annual
USDFY, 2015FY, 2016

Cash

28.5 m21.4 m

Accounts Receivable

10.4 m

Inventories

3.9 m7.2 m

Current Assets

83 m54.9 m
Quarterly
USDQ2, 2015Q3, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

7.5 m8.7 m8 m15.2 m65.2 m62.9 m

Accounts Receivable

9.3 m10.2 m

Inventories

2.4 m3.3 m4.7 m5.9 m7.3 m7.7 m

Current Assets

92.8 m89.1 m64.6 m58.3 m91.2 m88.7 m
Annual
USDFY, 2015FY, 2016

Net Income

(18.3 m)(28.7 m)

Depreciation and Amortization

1 m2.1 m

Inventories

(1.5 m)(3.3 m)

Accounts Payable

(206 k)596 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.9 m)(6.1 m)(6.9 m)(5 m)(9.5 m)(8.3 m)

Inventories

2.6 m2.4 m3.3 m4.7 m5.9 m7.3 m

Accounts Payable

2 m2.3 m3.4 m3.1 m4 m2.6 m
USDY, 2017

EV/EBIT

-71.4 x

Financial Leverage

1.5 x
Show all financial metrics

Entellus Medical Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Spirox (59)July 07, 2017$81 m
Report incorrect company information

Entellus Medical Company Life and Culture

Report incorrect company information